Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufac...
FDA Drug Recall #D-500-2013 — Class II — April 22, 2013
Recall Summary
| Recall Number | D-500-2013 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 22, 2013 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Mylan Pharmaceuticals Inc. |
| Location | Morgantown, WV |
| Product Type | Drugs |
| Quantity | 3,048 bottles |
Product Description
Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A. Made in India
Reason for Recall
Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..
Distribution Pattern
Nationwide
Lot / Code Information
Lot # ZRMB11004, Exp 09/13
Other Recalls from Mylan Pharmaceuticals Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0049-2021 | Class III | Candesartan Cilexetil and Hydrochlorothiazide T... | Oct 2, 2020 |
| D-1057-2020 | Class III | Tacrolimus Capsules, USP 5mg, 100-count bottle,... | Mar 23, 2020 |
| D-1031-2020 | Class II | Sotalol HCL Tablets, USP (AF) 80 mg, 100 count ... | Mar 9, 2020 |
| D-0791-2020 | Class II | Nizatidine Capsules, USP 150 mg, Rx Only, Mylan... | Jan 7, 2020 |
| D-0792-2020 | Class II | Nizatidine Capsules, USP 300 mg, Rx Only, Mylan... | Jan 7, 2020 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.